Navigation Links
Dialysis Corporation of America Announces $25 Million Credit Facility

LINTHICUM, Md., Nov. 5 /PRNewswire-FirstCall/ -- Dialysis Corporation of America (Nasdaq: DCAI) announced today that it has amended its secured revolving credit facility with KeyBank National Association to provide for up to $25,000,000 in financing. The three-year agreement provides for both base rate and LIBOR loans with interest rates to be based, respectively, upon either the bank's base rate or the London InterBank Offered Rate (LIBOR), plus an applicable margin.

Dialysis Corporation of America's President and CEO, Stephen Everett, commented, "As we go down the road of building our company through denovo development and select acquisitions, a concrete credit facility becomes critical. While we intend to further expand the credit line as opportunities warrant, we believe that we are in ideal shape to accomplish our goals for at least the next twelve to eighteen months. The confidence that the financial community has in our industry as a whole, and our company specifically, is underscored by the terms of this transaction."

The company plans to use its new credit facility to support its continued rapid growth and for general business purposes.

Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in the those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, increasing interest rates, the need for and availability of additional financing, satisfying the covenants and conditions of the credit facility, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's facilities can expand to provide profitability, the extensive regulation of dialysis operations, government rate determination for Medicare reimbursement, pricing pressure from private payors, and other risks detailed in the company's filings with the Securities and Exchange Commission, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2007.

Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's internet home page: .

CONTACT: For additional information, you may contact Stephen Everett, President and CEO of Dialysis Corporation of America, 1302 Concourse Drive, Suite 204, Linthicum, MD 21090; Telephone Number (410) 694-0500.

SOURCE Dialysis Corporation of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
2. Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment
3. Dialysis Patient Citizens Welcomes New Members to Board of Directors
4. Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award
5. Dialysis Corporation of America Reports Second Quarter 2008 Results
6. Bone Disease Test Shows Death Risk for Dialysis Patients
7. Automated, Wearable Kidney Offers Continuous Dialysis
8. U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India
9. Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri
10. Nocturnal Dialysis: A Better Way to Kidney Health
11. Dialysis Catheter Placement Makes Little Difference in Infection Risk
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... Bangalore, Karnataka (PRWEB) , ... November 27, 2015 ... ... the world, Health-E-minds, an innovative online platform for mental health and wellness consultation, ... KleverKid. , This partnership will bridge the knowledge gap experienced by parents and ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology: